Table 2 Rates of complete cytogenetic response (CCyR) and major molecular response (MMR) to imatinib and nilotinib in the ENESTnd trial.
From: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
| Â | % of patients | ||
|---|---|---|---|
| Â | Imatinib 400 mg QD | Nilotinib 300 mg BID | Nilotinib 400 mg BID |
CCyR | Â | Â | Â |
   6 months | 45 | 67 | 63 |
   12 months | 65 | 80 | 78 |
MMR | Â | Â | Â |
   3 months | 1 | 9 | 5 |
   6 months | 12 | 33 | 30 |
   9 months | 18 | 43 | 38 |
   12 months | 22 | 44 | 43 |
Progression to AP/BP | 4 | < 1 | < 1 |